Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease

R. Doody, Y. Wirth, F. Schmitt, H. J. Möbius

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Treatment of Alzheimer's disease (AD) that combats progressive functional deterioration can improve the patient's quality of life and reduce caregiver burden. Memantine, a moderate affinity N-methyl-D-aspartate receptor antagonist, reduces global deterioration in AD patients and provides cognitive and functional benefits relative to placebo. Two previous studies reported statistically significant benefits of memantine for overall functional ability on the Alzheimer Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADL 19), Functional Assessment Staging, and G2 scale. The present study reports a single-item analysis of the ADL scales from the two trials and shows that patients treated with memantine demonstrated a numerical advantage over placebo on all items assessed. These results help to translate the positive effects of memantine into specific aspects of functional ability, information that is relevant to AD patients and their families as well as to researchers interested in the assessment of functional ability in AD clinical trials.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalDementia and Geriatric Cognitive Disorders
Issue number2
StatePublished - 2004


  • Activities of daily living
  • Alzheimer's disease
  • Behavior
  • Memantine
  • Moderate to severe

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health


Dive into the research topics of 'Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease'. Together they form a unique fingerprint.

Cite this